08 October 2024
08 October 2024
The MHRA’s 2024/25 business plan focuses on improving service delivery for its customers, enabling access to new technologies.
The test is suitable for self-use by people aged 14 and above and can be administered by adults to children, starting at age two.
Kerecis’s fish-skin grafts led to higher and quicker healing rates compared to standard-of-care.
Cologuard Plus is the second version of the company’s colorectal cancer screening test, with increased genetic biomarkers and 30% lower false positive rates.
The devices are engineered with smaller tine lengths and diameters to enhance precision and minimise patient discomfort.
The funds will be formally announced at the UK’s International Investment Summit taking place on 14 October.
The UK's Presymptom Health was borne out of an MoD study with a view to commercialising AI-based infection research.
The study conducted by Medscape similarly found that whilst 51% of doctors are enthusiastic about the tech, many view it with serious apprehension.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
